

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 35/20, 7/26, 9/08 // 9/06		(11) International Publication Number: WO 98/51316
		A1 (43) International Publication Date: 19 November 1998 (19.11.98)
<p>(21) International Application Number: PCT/EP98/02613</p> <p>(22) International Filing Date: 4 May 1998 (04.05.98)</p> <p>(30) Priority Data: MI97A001091 9 May 1997 (09.05.97) IT</p> <p>(71) Applicant (<i>for all designated States except US</i>): VANDER WAY LIMITED [IE/IE]; 17 Dame Street, Dublin 2 (IE).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>): BARTORELLI, Luisa [IT/IT]; Via Fogazzaro, 20, I-20135 Milano (IT).</p> <p>(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).</p>		
<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, L.C, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		
<p>(54) Title: PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND THE USE OF COLOSTRUM FOR THE TREATMENT OF AFFECTIONS OF THE ORAL CAVITY</p> <p>(57) Abstract Pharmaceutical formulations containing animal colostrum for the treatment of affections of the oral cavity.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Austria	PS	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BI	Burundi	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	NX	Mexico	US	United States of America
CA	Canada	IT	Italy	NP	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KC	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CO	Colombia	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND THE
USE OF COLOSTRUM FOR THE TREATMENT OF AFFECTIONS OF THE
ORAL CAVITY

The present invention relates to pharmaceutical formulations containing animal colostrum for the treatment of affections of the oral cavity, and the use of colostrum for the treatment of said affections.

5 "Affections of the oral cavity" means, in particular, stomatitis, prosthetic stomatitis, gingivitis, periodontal diseases, pyorrhea alveolaris; mucositis, chemotherapy and radiotherapy sores and 10 ulcers; inflammations and ulcerations of the oral mucosa.

Poor oral hygiene, infections, local mechanical traumas, immune deficiencies, autoimmune disorders, avitaminosis, infective, toxic or irritating agents, systemic diseases, allergic sensitizations can be cited 15 among the known agents responsible for the above mentioned oral affections.

Therapy mainly depends on the etiologic agent: treatment usually consists, in addition to a better oral hygiene, in the administration of disinfectants, 20 astringents, antibacterials, such as chlorhexidine and quaternary ammonium salts; antibiotics, such as penicillin and tetracyclines; antimycotics, such as ketoconazole; steroids, such as dexamethasone, prednisolone and triamcinolone acetonide; local 25 anaesthetics, such as benzocaine and lidocaine; as well as the elimination of any mechanical factors such as malocclusion, substitution of prosthesis, and the like.

2

The use of medicaments such as antibiotics, antimycotics and steroids can, of course, involves untoward side-effects, or it can be limited or precluded by the conditions of the patient. An agent which, 5 although exerting remarkable antiinflammatory and antibacterial actions on the above cited conditions, involve no undesired side-effects is therefore strongly needed.

10 The present invention aims at overcoming the above mentioned problems by using topical pharmaceutical formulations containing equine, bovine or anyway mammal, but preferably equine, colostrum, for the treatment of affections of the oral cavity.

15 The present invention further relates to the use of equine, bovine or anyway mammal, but preferably equine, colostrum, as an agent for the treatment of the affections of the oral cavity.

20 Now it has surprisingly been found that colostrum, when administered to patients suffering from affections of the oral cavity, acts favourably exerting an antiinflammatory effect and restoring the physiological conditions of the buccal mucosa in a short time.

25 The pharmaceutical formulations of the invention comprise topical formulations containing powder or liquid colostrum in amounts up to 30% by volume of the formulation. The powder colostrum can be in the freeze-dried or sprayzed form.

30 More particularly, the formulations of the invention comprise collutories, liquid or in sachets to dilute before use, for the administration to the oral cavity by means of gurgles and washings with undiluted

3

solutions, spray for nebulizations, gingival gels for gingival massages, tooth-pastes or tablets to dissolve slowly in the mouth.

The compositions of the invention are prepared
5 according to the conventional pharmaceutical techniques
for the preparation of topical formulations for the
treatment of the oral cavity.

The formulations of the invention will be used by
the patient 1 to 3 times a day, particularly in the
10 morning and at night after brushing teeth.

According to a further aspect of the invention, the
formulations can contain colostrum mixed with
antibacterial agents, such as chlorhexidine and
benzidamine, antiinflammatory agents, local anaesthetics
15 such as lidocaine and benzocaine, vegetable extracts
having astringent or antiinflammatory action, essential
oils of sage, fennel, peppermint and clove, and the
like.

The formulations will also contain the conventional
20 excipients used for the preparation of oral topical
formulations.

The following examples illustrate formulations
according to the present invention.

EXAMPLE 1

25 20% Colostrum gingival gel

200 ml of gel contain (in % by volume):

colostrum 20

propylene glycol 1

chlorhexidine digluconate 0.5

30 methyl p-hydroxybenzoate 0.7

propyl p-hydroxybenzoate 0.7

4

essential oils and flavours	1.2%
micronized silica	10%
water q.s. to	200 ml

EXAMPLE 2

5 30% Colostrum collutory
100 ml of collutory contain (in % by volume):

colostrum	30
ethyl p-hydroxybenzoate	0.7
benzidamine	0.5
10 benzocaine	2.5
natural flavours	2
distilled water q.s. to	100 ml

EXAMPLE 3

20% Colostrum gingival gel
15 200 ml of gel contain (in % by volume):

colostrum	20
micronized silica	10
fennel essential oil	1.5
sage essential oil	2.0
20 methyl p-hydroxybenzoate	1.5
propyl p-hydroxybenzoate	1.5
chlorhexidine digluconate	0.5
natural flavours	1.5
distilled water q.s. to	200 ml.

CLAIMS

1. Topical pharmaceutical formulations containing colostrum for the treatment of affections of the oral cavity.
5. Pharmaceutical formulations according to claim 1, in which colostrum is equine, bovine or anyway mammal, but preferably equine, colostrum.
3. Formulations according to claims 1 and 2, in the form of collutory or tooth-paste containing powder or liquid colostrum.
10. Formulations according to the above claims, in which the powder colostrum is freeze-dried or sprayzed.
5. Formulations according to the above claims, further containing powder milk.
15. The use of colostrum for the preparation of a medicament for the treatment of affections of the oral cavity.

INTERNATIONAL SEARCH REPORT

National Application No
PCT/EP 98/02613

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/20 A61K7/26 A61K9/08 //A61K9/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 743 060 A (SARA LEE/DE N.V.) 20 November 1996	1-4,6
Y	see the whole document ---	5
X	WO 94 16675 A (HORSE VITALITY LTD.) 4 August 1994	1-5
Y	see claims -----	5

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

9 October 1998

Date of mailing of the international search report

20/10/1998

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 651 490 01
Fax: (+31-70) 340-3015

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/02613

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 743060	A 20-11-1996	CA 2175319	A	29-10-1996
WO 9416675	A 04-08-1994	IT 1263819	B	03-09-1996
		IT 1264637	B	04-10-1996
		AT 151278	T	15-04-1997
		AU 5833994	A	15-08-1994
		CA 2154652	A	04-08-1994
		DE 69309712	D	15-05-1997
		DE 69309712	T	23-10-1997
		DK 675708	T	20-10-1997
		EP 0675708	A	11-10-1995
		ES 2102813	T	01-08-1997
		GR 3024022	T	31-10-1997
		JP 8505630	T	18-06-1996
		US 5750149	A	12-05-1998
		ZA 9400507	A	05-09-1994